Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 15 • 2017 ACR/ARHP Annual Meeting
Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Kimberly Legault¹, Christopher Hillis¹, Cindy Yeung¹, Elie Akl², Marc Carrier³, Ricard Cervera⁴, Mark Crowther¹, Francesco Dentali⁵, Doruk Erkan⁶, Gerard Espinosa⁷, Munther A Khamashta⁸, Joerg Meerpohl⁹, Karen Moffatt¹⁰, Sarah O'Brien¹¹, Vittorio Pengo¹², Jacob Rand¹³, Ignasi Rodriguez¹⁴, Lisa Thom¹⁵, Holger Schunemann¹ and Alfonso Iorio¹, ¹McMaster University, Hamilton, ON, Canada, ²American University of Beirut, Beirut, Lebanon, ³University of Ottawa, Ottawa, ON, Canada, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Insubria University, Insubria, Italy, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada, ¹¹Nationwide Children's, Columbus, OH, ¹²Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹³NY Presbyterian Hospital, New York, NY, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵None (patient representative), Oxford, United Kingdom
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS), a rare disease, is characterized by the rapid onset of widespread thrombosis associated with multi-organ failure in patients meeting the…
Abstract Number: 17 • 2017 ACR/ARHP Annual Meeting
Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Jennifer Rammel¹, Martha Curry² and Marietta M. de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: While pediatric systemic lupus erythematosus (pSLE) represents only 20% of all SLE cases, pSLE patients often have more aggressive disease with multi-organ involvement. These…
Abstract Number: 108 • 2017 ACR/ARHP Annual Meeting
Impact of Antiphospholipid Syndrome Ibook on Medical Students’ Improvement of Knowledge: An International Randomized Controlled Experimental Study
Stephane Zuily¹, Laurent Phialy², Eloïse Germain², Ozan Unlu³, Virginie Dufrost⁴, Isabelle Clerc-Urmès⁴, Jessica R. Berman⁵, Michael Lockshin⁶, Denis Wahl⁷ and Doruk Erkan⁸, ¹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Auto-Immune Diseases; Inserm U1116; Lorraine University, Nancy, France, ²Lorraine University, Nancy School of Medicine, Nancy, France, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Nancy Academic Hospital, Nancy, France, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, NYC, NY, ⁷CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: iBooks, a free electronic book application by Apple, is well-suited for publishing interactive medical texts. To date, no iBook on Antiphospholipid Syndrome (APS) exists,…
Abstract Number: 1295 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Matthias Schneider¹, Jutta Richter¹, Anja Weiss², Angela Zink³ and Anja Strangfeld⁴, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁴Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: SLE pregnancies are complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal complications. With careful pre-pregnancy counseling and monitoring…
Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Gautam Sule¹, Levi F. Mazza¹, Nayef M. Kazzaz¹, Srilakshmi Yalavarthi¹, He Meng¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…
Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2761 • 2017 ACR/ARHP Annual Meeting
Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis
Ramadan A. Ali¹, He Meng¹, Srilakshmi Yalavarthi¹, Yogendra Kanthi¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: We have previously reported that antiphospholipid antibodies (aPL) activate neutrophils and thereby exaggerate neutrophil extracellular trap release (NETosis), which potentially contributes to the thrombotic…
Abstract Number: 2762 • 2017 ACR/ARHP Annual Meeting
Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Mériem Belhocine¹, Laetitia Coutte², Nicolas Martin Silva³, Nathalie Morel⁴, Gaelle Guettrot-Imbert⁴, Romain Paule⁴, Michel Dreyfus⁵, Micaela Fredi⁶, Odile Souchaud-Debouverie⁷, Jean Charles Piette⁸, Veronique Le Guern⁴ and Nathalie Costedoat-Chalumeau¹, ¹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ²Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Department of Internal Medicine, University Hospital Center of Caen, Caen, France, ⁴Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁵Department of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital Center of Caen, Caen, France, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Department of Internal Medicine, Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ⁸Department of Internal Medicine, Department of Internal Medicine, University Hospital Pitié-Salpétrière, Paris, France
Background/Purpose: The antiphospholipid syndrome (APS) is defined by a combination of arterial and/or venous thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies. There is a real…
Abstract Number: 1059 • 2016 ACR/ARHP Annual Meeting
Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy
Gabriela Hernandez-Molina¹, Itzel Gonzalez-Pérez², Carlos Pacheco² and Antonio R. Cabral³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Few studies have reported impaired health related quality of life (HRQoL) in patients with primary antiphospholipid syndrome (APS); however the causes of this outcome…
Abstract Number: 1060 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports
Noha Abdel-Wahab¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: A systematic review of case reports to summarize existing evidence in the literature regarding the association of APS and infection during childhood. Our aims…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 1068 • 2016 ACR/ARHP Annual Meeting
Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years
Gabriela Medina¹, Eduardo Briones-Garcia², Pilar Cruz-Dominguez³, Oscar I Florez-Durante⁴, Olga-Lidia Vera-Lastra⁵, Miguel A. Saavedra⁶ and Luis J. Jara⁷, ¹Clinical research unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Direction of Education and Research, Clinical Research Unit, Mexico, Mexico, ³Research Division, Hospital de Especialidades, Centro Médico La Raza, IMSS, Mexico, Mexico, ⁴Clinical researh Unit, Escuela Nacional de Ciencias Biológicas Instituto Politécnico Nacional, Mexico, Mexico, ⁵Rheumatology, Inst Mexicano Seguro Social, Mexico City, Mexico, ⁶Rheumatology, Centro Médico Nacional La Raza IMSS, México, Mexico, ⁷Direction of education and research, Hospital de Especialidades Centro Medico La Raza, Mexico City, Mexico
Background/Purpose: In some antiphospholipid syndrome (APS) patients, the antiphospholipid antibodies (aPL) becomes persistently negative. Discontinuation of anticoagulation has been proposed, however the long term follow-up…
Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting
Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Diego Hernández-Ramírez¹, Gabriela Hernandez-Molina², Carlos Núñez-Álvarez³, Miguel Astudillo-Angel⁴, Carlos Pacheco¹, Elizabeth Olivares-Martínez¹ and Antonio R. Cabral⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…
Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Ozan Unlu¹, Doruk Erkan², Maria Tektonidou³ and On Behalf of APS ACTION .⁴, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁴., New York, NY
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients. The prevalence of CVD risk factors…
Abstract Number: 1962 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Jason S Knight¹, Patrick S. Coit¹, He Meng¹, Srilakshmi Yalavarthi¹, Paul Renauer¹, Robert C Grenn¹, Levi F Mazza¹, Hui Wang², Daniel T Eitzman² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment of the thrombotic manifestations of antiphospholipid syndrome (APS) primarily focuses on inhibiting clotting pathways. In an effort to identify upstream inflammatory targets that…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].